Related Experiment Video
Updated: May 1, 2026

Right Ventricular Systolic Pressure Measurements in Combination with Harvest of Lung and Immune Tissue Samples in Mice
Published on: January 16, 2013
Inflammatory cytokines in pulmonary hypertension
Alexandra Groth, Bart Vrugt, Matthias Brock
1Division of Pulmonology, University Hospital Zurich, Rämistrasse 100, CH-8091 Zurich, Switzerland. lars.huber@usz.ch.
Pulmonary hypertension involves elevated pulmonary arterial pressure, leading to right heart failure. This review highlights inflammation, particularly Interleukin-6, as a key factor in its development and vascular remodeling.
Area of Science:
- Cardiology
- Pulmonology
- Immunology
Background:
- Pulmonary hypertension (PH) is a complex condition characterized by elevated pulmonary arterial pressure.
- Symptoms like dyspnea and fatigue can progress to fatal right heart failure without treatment.
- Pathogenesis involves vasoconstriction, vascular remodeling, and microthrombotic events, with inflammation increasingly recognized as a contributor.
Purpose of the Study:
- To review current clinical and experimental findings on inflammation in pulmonary hypertension.
- To specifically examine the role of Interleukin-6 (IL-6) in PH pathogenesis.
- To elucidate IL-6's contribution to vascular remodeling in pulmonary hypertension.
Main Methods:
- Literature review of clinical studies and experimental research.
- Focus on studies investigating inflammatory cytokines in PH.
- Analysis of data linking Interleukin-6 to vascular remodeling processes.
Main Results:
- Inflammation, driven by cytokines, is a significant factor in PH development.
- Interleukin-6 plays a crucial role in the inflammatory processes underlying PH.
- IL-6 is implicated in the vascular remodeling characteristic of pulmonary hypertension.
Conclusions:
- Inflammation is a critical component of pulmonary hypertension pathogenesis.
- Interleukin-6 is a key mediator in the inflammatory cascade of PH.
- Targeting IL-6 may offer therapeutic potential for pulmonary hypertension and its associated vascular remodeling.
Related Concept Videos
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
Acute Inflammation II: Local and Systemic Effects
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:

